Cited by 157Alzheimer's disease research and treatmentsProteoglycans and glycosaminoglycans researchNeuroscience and Neuropharmacology Research

Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology

Open access
Morawski, Markus, Brückner, Gert, Jäger, Carsten, Seeger, Gudrun, Matthews, Russel T, Arendt, Thomas·2012·Brain Pathology

Abstract

Brain extracellular matrix (ECM) is organized in specific patterns assumed to mirror local features of neuronal activity and synaptic plasticity. Aggrecan‐based perineuronal nets (PNs) and brevican‐based perisynaptic axonal coats (ACs) form major structural phenotypes of ECM contributing to the laminar characteristics of cortical areas. In Alzheimer's disease (AD), the deposition of amyloid proteins and processes related to neurofibrillary degeneration may affect the integrity of the ECM scaffold. In this study we investigate ECM organization in primary sensory, secondary and associative areas of the temporal and occipital lobe. By detecting all major PN components we show that the distribution, structure and molecular properties of PNs remain unchanged in AD. Intact PNs occurred in close proximity to amyloid plaques and were even located within their territory. Counting of PNs revealed no significant alteration in AD. Moreover, neurofibrillary tangles never occurred in neurons associated with PNs. ACs were only lost in the core of amyloid plaques in parallel with the loss of synaptic profiles. In contrast, hyaluronan was enriched in the majority of plaques. We conclude that the loss of brevican is associated with the loss of synapses, whereas PNs and related matrix components resist disintegration and may protect neurons from degeneration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1750-3639.2011.00557.x

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most previous studies support a beneficial role of PNN in Alzheimer's disease mouse models.

    “In summary, most of the previous studies are in support of beneficial role of PNN in AD mouse model.”

    From Disrupted structural connectivity in ArcAβ mouse model of Aβ amyloidosis (2020) · cites this paper as Morawski et al., 2012

    The Discussion (Functional implications; page not provided) describes potential neuroprotective actions of perineuronal nets, including protection against amyloid toxicity in vitro. The Discussion (Area-specific laminar distribution patterns; page not provided) also cites one AD mouse-model study in which perineuronal nets were largely unchanged. These passages do not establish that most previous studies found a beneficial role in AD mouse models. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Loss of PNN CS-GAGs appears to occur independently to PNN core proteins (aggrecan and brevican), which remain stable in postmortem AD brain tissue.

    “Intriguingly, the loss of PNN CS-GAGs appears to occur independently to PNN core proteins (i.e., aggrecan and brevican), which remain stable in postmortem AD brain tissue (Brückner et al. 1999; Morawski et al. 2010a; Morawski et al. 2012; Lendvai et al. 2013; Howell et al. 2015).”

    From Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration (2024) · cites this paper as Morawski et al. 2012

    The Discussion (Technical considerations; page not available) reports that prolonged post-mortem delay substantially reduced WFA binding to chondroitin-associated sites while aggrecan reactivity was virtually unaffected. But it attributes that loss to post-mortem changes, not AD: WFA and VVA binding was retained in well-preserved AD and control tissue. The paper also identifies brevican with perisynaptic axonal coats rather than PNNs and reports its loss in plaque cores. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Neurons with intact PNN never deposit neurofibrillary tangles.

    “neurons having intact PNN never deposits neurofibrillary tangles (Morawski et al., 2012)”

    From Disrupted structural connectivity in ArcAβ mouse model of Aβ amyloidosis (2020) · cites this paper as Morawski et al., 2012

  • Whether perineuronal nets are altered in Alzheimer's disease remains controversial.

    “but whether PNNs are altered in AD remains controversial.”
  • In Alzheimer's disease, cortical and subcortical neurons enwrapped by a perineuronal net are less frequently affected by neurofibrillary degeneration than neurons without a perineuronal net.

    “In previous studies we could demonstrate that in AD cortical and subcortical neurons are constantly less frequently affected by neurofibrillary degeneration if they are enwrapped by a specialized form of the ECM, the so-called PN.2, 3”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Morawski, M., Brückner, G., Jäger, C., Seeger, G., Matthews, R. T., & Arendt, T.
Affiliations
  • Leipzig University (DE)
  • SUNY Upstate Medical University (US)
Venue
Brain Pathology
Publisher
Wiley
Published
2012-01-13
Volume
22
Issue
4
Pages
547-561
ISSN
  • 1015-6305 (ISSN-L)
  • 1750-3639
OpenAlex
W1543143540
Cited by
157
References
105
Citations by year
2026: 6 · 2025: 10 · 2024: 17 · 2023: 9 · 2022: 11 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 14 · 2017: 10 · 2016: 9 · 2015: 8 · 2014: 12 · 2013: 10 · 2012: 5
FWCI
5.80
Type
journal article
Language
en
Open access
Locations
  • Brain Pathology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
Funders
  • National Institute on Aging (P30AG019610)
  • National Institute of Neurological Disorders and Stroke (U24NS072026)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
Alzheimer's disease, extracellular matrix, perineuronal nets, brevican, aggrecan, hyaluronic acid, amyloid plaques, neurofibrillary tangles, synaptic loss, temporal lobe, occipital lobe, cortical laminar organization
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Axons, Brain, Extracellular Matrix, Female, Humans, Male, Synapses, Microscopy, Confocal, Aggrecans, Brevican

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review